You are here: Industry Insights > SARS-CoV-2

News List

GenScript Files for EUA of Rapid SARS-CoV-2 Neutralization Antibody Detection Kit americanpharmaceuticalreview
June 15, 2020
GenScript Biotech announced the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.
J&J accelerates clinical trial of investigational COVID-19 vaccine europeanpharmaceuticalreview
June 15, 2020
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
COVID-19 mouse model will speed search for drugs, vaccines worldpharmanews
June 11, 2020
The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July worldpharmanews
June 11, 2020
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
Daewoong finds niclosamide effective against Covid-19 in animal tests pharmaceutical-technology
June 11, 2020
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
Scientists identify targets for COVID-19 vaccine using cancer immunotherapy tools worldpharmanews
June 10, 2020
Cancer researchers at Children's Hospital of Philadelphia (CHOP) have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine...
A2A Pharmaceuticals Collaborates with Laxai Life Sciences contractpharma
June 10, 2020
Will co-develop SARS-CoV-2 main proteases inhibitors for the treatment of COVID-19.
EU lockdowns saved more than 3m lives, research indicates pharmatimes
June 09, 2020
Millions of lives have been saved by non-pharmaceutical interventions to the coronavirus pandemic such as nationwide large-scale lockdowns, suggests a new analysis by researchers from Imperial College London.
ImmunoPrecise, Integrated Biotherapeutics, NIH Collaborate to Study Structural Details of Antibodies for COVID-19 americanpharmaceuticalreview
June 09, 2020
Immunoprecise Antibodies announced it is collaborating in a multi-company effort with the laboratory of Dr. Frederick Dyda at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) ...
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients worldpharmanews
June 08, 2020
Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.(1)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page